EARNING RECAP

Abbvie INC

#ABBV 2019 EPS:(Actual vs Estimate) Revenue(Actual vs Estimate) Stock price move next bell High Low Notes
Q1 adjusted $2.14 est. $2.06 $7.83B est. $7.76B +.85% ($79.34 closing price) $80.47 $76.91 raises FY19 adj. EPS view to $8.73-$8.83 from $8.65-$8.75; Humira sales $3.215B up 7.1%; Hematologic oncology portfolio revenue $1.173B up 42.8%
#ABBV 2018 EPS:(Actual vs Estimate) Revenue(Actual vs Estimate) Stock price move next bell High Low Notes
Q4 adjusted $1.90 est. $1.94 $8.305B est. $8.38B -6.22% ($80.54 closing price) $82.61 $79.43 sees FY19 adjusted EPS view $8.65-$8.75 est. $8.71; Q4 Humira sales up.5%; hematologic oncology revenue $1.13B
Q3 $2.14 est. $2.02 $8.24B est. $8.23B -.81% ($79.56 closing price) $84.42 $78.76 announces 2019 dividend increase of 11.5%; Q3 global sales of HUMIRA $5.124B; sees Q4 EPS $1.89- $1.91 est. $1.96, sees FY18 U.S. Humira sales $13.7B
Q2 adjusted $2 est. $1.97 adjusted $8.258B est. $8.21B -3.60% ($90.56 closing) $92.27 $88.77 raises FY18 adjusted EPS view to $7.76-$7.86 from $7.66-$7.76 FY18 est. $7.81; Q2 global HUMIRA sales up 10% $5.185B,
Q1 adjusted $1.87 est. $1.79 $7.93B est. $7.6B +6.06% ($97.44 closing) $98.55 $93.58 Q1 Global Humira sales up 14.4%or$4.709B,HCV net revenue $919M, Buyback $7.5B common stock
#ABBV 2017 EPS:(Actual vs Estimate) Revenue(Actual vs Estimate) Stock price move next bell High Low Notes
Q4 $1.48 est. $1.44 $7.74B est. $7.53B. +13.77% ( $123.21 closing price) $125.86 $113.50 raises FY18 adjusted EPS view to $7.33-$7.43 from $6.37-$6.57 FY18 est. $6.59.

Please select phase first
Disclaimer! This is NOT an investment advice. The data result herein is purely speculation only. You must do your own due diligence and mitigate your risk. You acknowledge that TradersFish.com will not be held responsible and accountable for any losses you may incur using our Biotech Data Calculator. Please consult your own financial adviser before executing trades.